You are here:

Archived: buprenorphine transdermal patch (BuTrans)

Advice

Following a 2nd resubmission

buprenorphine transdermal patches (Butrans®) are not recommended for use within NHS Scotland for the treatment of severe opioid responsive pain conditions, which are not adequately responding to non-opioid analgesics.

In the patient population considered in this submission, severe osteoarthritis pain in elderly patients whose pain is not adequately controlled by non-opioid analgesics, or for whom other analgesics are not suitable, buprenorphine transdermal 7-day patch was superior to placebo and similar in efficacy to comparator agents.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by the SMC.

The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: buprenorphine transdermal patch (BuTrans)
SMC Drug ID: 234/06
Manufacturer: Napp Pharmaceuticals Ltd
Indication: For the treatment of severe opiod responsive pain conditions which are not adequately responding to non-opiod analgesics
BNF Category:
Sub Category: 4.7 Analgesics
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 11 August 2008

Current Advice

Resubmission 12 January 2009

Archived Advice

Resubmission 7 May 2007
Full submission 13 February 2006

Back